Characteristic | Crude RR (CI95%) | P value | Adjusted RR (CI95) | P-value |
---|---|---|---|---|
Age in years | Â | Â | Â | Â |
18–29 | 1 |  | 1 |  |
30–39 | 0.92 (0.76–1.12) | 0.420 | 0.91 (0.76–1.09) | 0.305 |
≥ 40 | 0.98 (0.80–1.20) | 0.830 | 0.88 (0.73–1.06) | 0.179 |
Sex | ||||
Female | 1 | Â | 1 | Â |
Male | 1.15 (0.98–1.34) | 0.090 | 1.08 (0.94–1.26) | 0.285 |
Number of IAC sessions provided | ||||
> 3 Sessions | 1 |  | 1 |  |
3 Sessions | 1.31 (1.13–1.53) | < 0.001 | 1.33 (1.15–1.53) | < 0.001 |
Baseline non-suppressed viral load test result (Copies/ml) | ||||
≥ 10,000 | 1 |  | 1 |  |
5,000–10,000 | 1.10 (0.80–1.52) | 0.557 | 1.24 (0.89–1.73) | 0.200 |
1,000–4,999 | 1.52 (1.27–1.81) | < 0.001 | 1.47 (1.25–1.73) | < 0.001 |
ART regimen at time of VL non-suppression | ||||
EFV Based regimen | 1 | Â | 1 | Â |
NVP Based regimen | 0.91 (0.69–1.21) | 0.536 | 0.91 (0.69–1.19) | 0.482 |
ATV/r Based regimen | 1.34 (1.06–1.69) | 0.013 | 1.32 (1.05–1.66) | 0.017 |
DTG Based regimen | 1.68 (1.44–1.96) | < 0.001 | 1.61 (1.37–1.88) | < 0.001 |
LPV/r Based regimen | 1.02 (0.67–1.56) | 0.914 | 0.99 (0.66–1.48) | 0.963 |